AptarGroup, Inc. (ATR)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AptarGroup, Inc. (ATR) trades at $126.69 with AI Score 75/100 (Grade A). AptarGroup, Inc. develops and manufactures a wide array of dispensing, sealing, and material science solutions. Market cap: $8.09B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026ATR stock analysis for 2026: Analysts have set a consensus price target of $161.43 for AptarGroup, Inc., suggesting 27.4% upside from the current price of $126.69. The AI MoonshotScore is 75/100, indicating a strong bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
ATR: 5/7 perspectives are bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AptarGroup, Inc. (ATR) Healthcare & Pipeline Overview
AptarGroup, Inc. delivers dispensing, sealing, and active material science solutions across diverse markets, including pharmaceuticals, beauty, and food and beverage. With a focus on innovative packaging and delivery systems, AptarGroup leverages strategic partnerships and a global presence to maintain a competitive edge in the healthcare and consumer goods sectors.
What Is the Investment Thesis for ATR?
AptarGroup, Inc. presents a compelling investment case based on its diversified market segments and innovative product offerings. With a market capitalization of $8.09B and a P/E ratio of 19.2, the company demonstrates financial stability. A profit margin of 10.0% and a gross margin of 29.0% reflect efficient operations. Key growth catalysts include expanding its presence in the Pharma segment through innovative drug delivery systems and leveraging partnerships for sustainable packaging solutions. Potential risks include fluctuating raw material costs and increasing competition within the dispensing solutions market. The company's beta of 0.44 suggests lower volatility compared to the broader market, making it a noteworthy option for risk-averse investors. The dividend yield of 1.56% provides a steady income stream.
Based on FMP financials and quantitative analysis
ATR Key Highlights
- Market Cap of $8.09B indicates substantial investor confidence and market valuation.
- P/E Ratio of 19.2 suggests a reasonable valuation relative to earnings.
- Profit Margin of 10.0% demonstrates solid profitability in a competitive market.
- Gross Margin of 29.0% reflects efficient cost management in manufacturing and distribution.
- Dividend Yield of 1.56% provides a consistent return for shareholders.
Who Are ATR's Competitors?
ATR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GMED Globus Medical, Inc. | $80.89 | +0.97% | 11B | 97 |
| MOH Molina Healthcare, Inc. | $227.70 | -0.94% | $11.86B | 80 |
| MASI Masimo Corporation | $179.95 | +0.00% | $9.42B | 55 |
| HSIC Henry Schein, Inc. | $86.62 | +0.22% | $9.87B | 71 |
| HALO Halozyme Therapeutics, Inc. | $80.78 | +1.67% | $9.58B | 94 |
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ATR's Key Strengths?
- Diversified product portfolio across multiple sectors.
- Strong relationships with leading pharmaceutical, beauty, and food and beverage companies.
- Global presence with operations in Asia, Europe, Latin America, and North America.
- Focus on innovation and sustainable solutions.
What Are ATR's Weaknesses?
- Exposure to fluctuating raw material costs.
- Dependence on key suppliers for certain components.
- Potential impact from regulatory changes in healthcare and packaging.
- Competition from established players and emerging market entrants.
What Could Drive ATR Stock Higher?
- Expansion of Pharma segment through innovative drug delivery systems.
- Launch of new sustainable packaging solutions in partnership with PureCycle Technologies LLC.
- Penetration of emerging markets in Asia and Latin America.
- Development of active material science solutions for enhanced product protection.
What Are the Key Risks for ATR?
- Insider selling — insiders were net sellers of roughly $3.0M recently.
- Fluctuations in raw material costs affecting profitability.
- Increasing competition from alternative packaging solutions.
- Regulatory changes in healthcare and packaging impacting product compliance.
- Economic downturns affecting consumer spending on beauty and personal care products.
What Are the Growth Opportunities for ATR?
- Expansion in the Pharma Segment: AptarGroup can capitalize on the growing demand for advanced drug delivery systems, particularly in injectable and respiratory treatments. The global drug delivery market is projected to reach $240 billion by 2028, offering significant growth potential. By developing innovative solutions like metered dose inhaler valves and elastomer components, AptarGroup can strengthen its market position and drive revenue growth. This expansion is expected to contribute significantly to the company's revenue within the next 3-5 years.
- Strategic Partnerships for Sustainable Packaging: Collaborating with companies like PureCycle Technologies LLC allows AptarGroup to develop sustainable packaging solutions using recycled polypropylene. With increasing consumer and regulatory focus on sustainability, this initiative can attract environmentally conscious customers and enhance the company's brand image. The market for sustainable packaging is estimated to reach $440 billion by 2027, providing a substantial growth opportunity for AptarGroup. These partnerships are expected to yield tangible results within the next 2-3 years.
- Penetration of Emerging Markets: Expanding its presence in emerging markets, particularly in Asia and Latin America, can drive significant growth for AptarGroup. These regions are experiencing rapid economic growth and increasing demand for packaged goods and healthcare products. By establishing local manufacturing facilities and distribution networks, AptarGroup can cater to the specific needs of these markets and gain a competitive advantage. This expansion is expected to contribute to long-term revenue growth over the next 5-7 years.
- Innovation in Active Material Science Solutions: Investing in research and development to create active material science solutions can differentiate AptarGroup from its competitors. These solutions can enhance product protection, extend shelf life, and improve consumer experience. The market for active packaging is projected to reach $40 billion by 2025, offering a lucrative growth opportunity. By focusing on innovation, AptarGroup can secure patents and establish a technological edge. These innovations are expected to generate new revenue streams within the next 3-4 years.
- Leveraging Digital Health Platforms: Collaborating with companies like Sonmol to develop digital therapies and services platforms can enhance AptarGroup's offerings in the healthcare sector. These platforms can improve patient adherence, monitor treatment outcomes, and provide personalized healthcare solutions. The digital health market is experiencing rapid growth, with a projected value of $660 billion by 2025. By integrating its dispensing solutions with digital health platforms, AptarGroup can create a comprehensive ecosystem and drive value for its customers. This integration is expected to yield significant results within the next 2-3 years.
What Opportunities Does ATR Have?
- Expansion in emerging markets with growing demand for packaged goods.
- Strategic partnerships to develop sustainable packaging solutions.
- Innovation in active material science solutions for enhanced product protection.
- Leveraging digital health platforms to improve patient adherence and treatment outcomes.
What Threats Does ATR Face?
- Increasing competition from alternative packaging solutions.
- Economic downturns affecting consumer spending on beauty and personal care products.
- Disruptions in the supply chain due to geopolitical events or natural disasters.
- Changes in consumer preferences and demand for sustainable products.
What Are ATR's Competitive Advantages?
- Proprietary Technology: AptarGroup's patented dispensing and sealing technologies create a barrier to entry for competitors.
- Established Customer Relationships: Long-standing relationships with major pharmaceutical, beauty, and food and beverage companies provide a stable revenue base.
- Diversified Market Segments: Operating across multiple sectors reduces reliance on any single market, mitigating risk.
- Global Presence: A wide geographic footprint allows AptarGroup to serve customers worldwide and capitalize on growth opportunities in emerging markets.
What Does ATR Do?
AptarGroup, Inc., incorporated in 1992 and headquartered in Crystal Lake, Illinois, is a global leader in providing a wide range of dispensing, sealing, and material science solutions. The company operates through three primary segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma segment offers pumps for nasal allergy treatments, metered dose inhaler valves for respiratory ailments, elastomer components for injectable primary packaging, and active material science solutions. The Beauty + Home segment provides pumps, closures, aerosol valves, accessories, and sealing solutions for the personal care, home care, and beauty markets. The Food + Beverage segment offers dispensing and non-dispensing closures, elastomeric flow control components, spray pumps, and aerosol valves. AptarGroup sells its products through its own sales force and via independent representatives and distributors across Asia, Europe, Latin America, and North America. The company has established strategic partnerships, including collaborations with PureCycle Technologies LLC to develop ultra-pure recycled polypropylene for dispensing applications and with Sonmol to develop a digital therapies and services platform targeting respiratory and other diseases. AptarGroup's solutions are integral to enhancing product functionality, consumer experience, and supply chain efficiency for its diverse customer base.
What Products and Services Does ATR Offer?
- Provides dispensing solutions for nasal allergy treatments.
- Manufactures metered dose inhaler valves for respiratory ailments.
- Offers elastomer components for injectable primary packaging.
- Develops active material science solutions.
- Supplies pumps, closures, and aerosol valves for personal and home care markets.
- Provides dispensing and non-dispensing closures for the food and beverage markets.
- Offers spray pumps and aerosol valves to the food and beverage industries.
How Does ATR Make Money?
- Manufactures and sells dispensing, sealing, and material science solutions.
- Operates through three segments: Pharma, Beauty + Home, and Food + Beverage.
- Generates revenue through direct sales and distribution networks.
- Focuses on innovation and strategic partnerships to enhance product offerings.
What Industry Does ATR Operate In?
AptarGroup, Inc. operates within the medical instruments and supplies industry, which is experiencing growth driven by increasing healthcare expenditure and demand for advanced drug delivery systems. The market is competitive, with key players focusing on innovation and strategic partnerships. AptarGroup's focus on dispensing, sealing, and material science solutions positions it well to capitalize on the increasing demand for specialized packaging and delivery systems in the pharmaceutical, beauty, and food and beverage sectors. Competitors include GMED: Globus Medical, Inc., MOH: Molina Healthcare, Inc., MASI: Masimo Corporation, HSIC: Henry Schein, Inc., and HALO: Halozyme Therapeutics, Inc.
Who Are ATR's Key Customers?
- Pharmaceutical companies requiring drug delivery systems.
- Beauty and personal care brands needing dispensing and packaging solutions.
- Home care product manufacturers utilizing closures and aerosol valves.
- Food and beverage companies requiring dispensing and non-dispensing closures.
AptarGroup, Inc. Financial Trajectory
AptarGroup, Inc. (ATR) reported $982.9M in revenue for Q1 2026, reflecting 2.1% growth compared to the prior quarter. The company recorded net income of $72.7M, with diluted EPS of $1.12. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, ATR averaged $1.46 in diluted EPS.
Company Profile
AptarGroup, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Crystal Lake, US. The company is led by CEO Stephan Tanda. ATR has traded publicly since 1993.
How AptarGroup, Inc. Is Valued
AptarGroup, Inc. carries a market capitalization of $8.09B, placing it in the mid-cap category. Relative to its peer group, ATR's quantitative score of 75/100 is roughly in line with the peer average of 79/100.
ROE 14%Key Financial Metrics
Return on equity for AptarGroup, Inc. stands at 14.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.6%, showing how much profit it generates from its asset base. ATR trades at a trailing price-to-earnings ratio of 19.20, below the Healthcare sector average of ~23x. Its free cash flow yield is 4.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.66 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.2%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
AptarGroup, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.02 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project AptarGroup, Inc. revenue of about $3.98B for fiscal 2026, with EPS near $5.50. The estimate reflects 7 contributing analysts.
Net buyingInsider Activity
Over the past six months, AptarGroup, Inc. insiders filed 29 SEC Form 4 transactions — 13 sales and 16 purchases. On net that is roughly 21K shares acquired (about $3.0M) — insiders putting money in tends to read as conviction.
ATR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in AptarGroup's future performance, indicating that executives believe the stock is undervalued.
- Community sentiment has been increasingly optimistic, with discussions highlighting the company's innovative product pipeline and sustainability initiatives.
- Analysts are noting a growing demand for AptarGroup's packaging solutions in various sectors, reflecting a positive market trend.
- The company has been strengthening its position in emerging markets, which could drive future revenue growth and market share expansion.
Bear Case
- Concerns about potential supply chain disruptions have surfaced, raising questions about the company's operational efficiency in the near term.
- Some community members express skepticism regarding the company's ability to sustain its recent growth, citing increased competition in the packaging industry.
- Recent quarterly results have led to mixed reviews, with some investors worried about margin pressures affecting profitability.
- Broader economic uncertainties may impact consumer spending, which could adversely affect AptarGroup's sales in the upcoming quarters.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $983M | $73M | $1.12 |
| Q4 2025 | $963M | $74M | $1.13 |
| Q3 2025 | $961M | $128M | $1.92 |
| Q2 2025 | $966M | $112M | $1.67 |
Based on FMP financials and quantitative analysis
ATR Latest News
-
Aptar Releases 2025 Corporate Sustainability Report
businesswire.com · Jun 18, 2026
-
Is West Pharmaceutical Stock Outperforming the S&P 500?
Yahoo! Finance: ATR News · Jun 15, 2026
-
Aptargroup Insider Sold Shares Worth $577,895, According to a Recent SEC Filing
MT Newswires · Jun 10, 2026
-
AptarGroup, Inc. (ATR) Presents at 16th Annual Wells Fargo Industrials & Materials Conference Transcript
seekingalpha.com · Jun 10, 2026
ATR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATR.
Price Targets
Consensus target: $161.43
ATR MoonshotScore
What does this score mean?
The MoonshotScore rates ATR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Aptar Releases 2025 Corporate Sustainability Report
Is West Pharmaceutical Stock Outperforming the S&P 500?
Aptargroup Insider Sold Shares Worth $577,895, According to a Recent SEC Filing
AptarGroup, Inc. (ATR) Presents at 16th Annual Wells Fargo Industrials & Materials Conference Transcript
Latest AptarGroup, Inc. Analysis
Leadership: Stephan Tanda
Chairman, President and Chief Executive Officer
Stephan Tanda serves as the Chairman, President, and Chief Executive Officer of AptarGroup, Inc. Prior to joining AptarGroup, he held various leadership positions at Royal DSM N.V., including Member of the Managing Board and Executive Vice President of DSM Nutritional Products. He has extensive experience in the healthcare, nutrition, and materials science industries. Tanda holds a Master of Science degree in Chemical Engineering from Delft University of Technology in the Netherlands.
Track Record: Under Stephan Tanda's leadership, AptarGroup has focused on strategic growth initiatives, including expanding its presence in emerging markets and investing in innovative solutions. He has overseen key acquisitions and partnerships that have strengthened the company's market position. Tanda has also championed sustainability efforts, driving the development of eco-friendly packaging solutions. He is managing 13000 employees.
What Investors Ask About AptarGroup, Inc. (ATR) — Healthcare
What does AptarGroup, Inc. do?
AptarGroup, Inc. specializes in the design and manufacture of a wide range of dispensing, sealing, and material science solutions. The company operates across three key segments: Pharma, Beauty + Home, and Food + Beverage. In the pharmaceutical sector, AptarGroup provides critical components like metered dose inhaler valves and injectable packaging. For the beauty and home care markets, they offer pumps, closures, and aerosol valves. In the food and beverage industry, AptarGroup provides dispensing and non-dispensing closures. The company's solutions are integral to enhancing product functionality and consumer experience.
What do analysts say about ATR stock?
Analyst consensus on AptarGroup, Inc. (ATR) reflects a generally positive outlook, driven by the company's diversified market segments and consistent financial performance. Key valuation metrics, such as the P/E ratio of 19.2, suggest a reasonable valuation relative to earnings. Growth considerations include the company's expansion in the Pharma segment and strategic partnerships for sustainable packaging. While analysts acknowledge potential risks like fluctuating raw material costs, the overall sentiment is optimistic, supported by AptarGroup's established market position and innovative product offerings. No buy or sell recommendations are made here.
What are the main risks for ATR?
AptarGroup, Inc. faces several key risks, including fluctuations in raw material costs, which can impact profitability. Increasing competition from alternative packaging solutions and emerging market entrants poses a threat to market share. Regulatory changes in the healthcare and packaging industries could affect product compliance and increase operational costs. Economic downturns may reduce consumer spending on beauty and personal care products, impacting revenue. Disruptions in the supply chain due to geopolitical events or natural disasters could also affect production and distribution.
How does AptarGroup, Inc. navigate regulatory approval processes?
AptarGroup, Inc. navigates regulatory approval processes by maintaining a dedicated regulatory affairs team that closely monitors changes in regulations across its operating regions. The company adheres to stringent quality control standards and conducts thorough testing to ensure its products meet all applicable requirements. AptarGroup also collaborates with regulatory agencies to address any concerns and obtain necessary approvals in a timely manner. This proactive approach helps the company minimize risks and maintain compliance in the highly regulated healthcare and packaging industries.
How does AptarGroup, Inc. manage patent expiration risks?
AptarGroup, Inc. manages patent expiration risks through continuous innovation and a robust intellectual property strategy. The company invests in research and development to create new and improved products, securing patents to protect its innovations. AptarGroup also focuses on building strong customer relationships and providing value-added services to differentiate its products from generic alternatives. This proactive approach helps the company mitigate the impact of patent expirations and maintain a competitive edge in the market. They also seek to extend product lifecycles by developing new applications for existing technologies.
What are the key factors to evaluate for ATR?
AptarGroup, Inc. (ATR) holds an AI score of 75/100 (high). P/E: 19.2x vs the S&P 500's ~20-25x. Analysts target $161.43 (+27%). Not financial advice.
How frequently does ATR data refresh on this page?
ATR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ATR's recent stock price performance?
AptarGroup, Inc. (ATR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio across multiple sectors. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are as of the latest available reporting period.